Skip to main content
Top
Published in: Surgical Endoscopy 8/2015

01-08-2015

Does the cost of robotic cholecystectomy translate to a financial burden?

Authors: Alexander Rosemurgy, Carrie Ryan, Richard Klein, Prashant Sukharamwala, Thomas Wood, Sharona Ross

Published in: Surgical Endoscopy | Issue 8/2015

Login to get access

Abstract

Introduction

Robotic application to cholecystectomy has dramatically increased, though its impact on cost of care and reimbursement has not been elucidated. We undertook this study to evaluate and compare cost of care and reimbursement with robotic versus laparoscopic cholecystectomy.

Methods and procedures

The charges and reimbursement of all robotic and laparoscopic cholecystectomies at one hospital undertaken from June 2012 to June 2013 were determined. Operative duration is defined as time into and time out of the operating room. Data are presented as median data. Comparisons were undertaken using the Mann–Whitney U-test with significance accepted at p ≤ 0.05.

Results

Robotic cholecystectomy took longer (47 min longer) and had greater charges ($8,182.57 greater) than laparoscopic cholecystectomy (p < 0.05 for each). However, revenue, earnings before depreciation, interest, and taxes (EBDIT), and Net Income were not impacted by approach.

Conclusions

Relative to laparoscopic cholecystectomy, robotic cholecystectomy takes longer and has greater charges. Revenue, EBDIT, and Net Income are similar after either approach; this indicates that costs with either approach are similar. Notably, this is possible because much of hospital-based costs are determined by cost allocation and not cost accounting. Thus, the cost of longer operations and costs inherent to the robotic approach for cholecystectomy do not translate to a perceived financial burden.
Literature
1.
2.
go back to reference Peters J (2006) Laparoscopic treatment of gastroesophageal reflux disease and hiatal hernia. The SAGES Manual: fundamentals of laparoscopy, thoracoscopy, and GI endoscopy, vol 2. Springer, New York, pp 208–224 Peters J (2006) Laparoscopic treatment of gastroesophageal reflux disease and hiatal hernia. The SAGES Manual: fundamentals of laparoscopy, thoracoscopy, and GI endoscopy, vol 2. Springer, New York, pp 208–224
3.
go back to reference Sandler R, Everhart J, Donowitz M, Adams E, Cronin K, Goodman C et al (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122(5):1500–1511PubMedCrossRef Sandler R, Everhart J, Donowitz M, Adams E, Cronin K, Goodman C et al (2002) The burden of selected digestive diseases in the United States. Gastroenterology 122(5):1500–1511PubMedCrossRef
4.
go back to reference Barnes W, Hoddinott K, Mundy S, Williams M (2001) Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. Surg Innov 18(2):119–129CrossRef Barnes W, Hoddinott K, Mundy S, Williams M (2001) Transoral incisionless fundoplication offers high patient satisfaction and relief of therapy-resistant typical and atypical symptoms of GERD in community practice. Surg Innov 18(2):119–129CrossRef
5.
go back to reference Rosemurgy A, Paul H, Madison L, Luberice K, Donn N, Vice M et al (2012) A single institution’s experience and journey with over 1000 laparoscopic fundoplications for GERD. Am Surg 78(9):917–925PubMed Rosemurgy A, Paul H, Madison L, Luberice K, Donn N, Vice M et al (2012) A single institution’s experience and journey with over 1000 laparoscopic fundoplications for GERD. Am Surg 78(9):917–925PubMed
6.
go back to reference Rosemurgy A, Donn N, Paul H, Luberice K, Ross S (2011) Gastroesophageal reflux disease. Surg Clin North Am 91(5):1015–1029PubMedCrossRef Rosemurgy A, Donn N, Paul H, Luberice K, Ross S (2011) Gastroesophageal reflux disease. Surg Clin North Am 91(5):1015–1029PubMedCrossRef
7.
go back to reference Demyttenaere S, Bergman S, Pham T, Anderson J, Dettorre R, Melvin W et al (2010) Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surg Endosc 24(4):854–858PubMedCrossRef Demyttenaere S, Bergman S, Pham T, Anderson J, Dettorre R, Melvin W et al (2010) Transoral incisionless fundoplication for gastroesophageal reflux disease in an unselected patient population. Surg Endosc 24(4):854–858PubMedCrossRef
8.
go back to reference Voitk A, Joffe J, Alvarez C, Rosenthal G (1999) Factors contributing to laparoscopic failure during the learning curve for laparoscopic Nissen fundoplication in a community hospital. Laparoendosc Adv Surg Tech A 9(3):243–249CrossRef Voitk A, Joffe J, Alvarez C, Rosenthal G (1999) Factors contributing to laparoscopic failure during the learning curve for laparoscopic Nissen fundoplication in a community hospital. Laparoendosc Adv Surg Tech A 9(3):243–249CrossRef
9.
go back to reference Cadière G, Buset M, Muls V, Rajan A, Rösch T, Eckardt A et al (2008) Antireflux transoral incisionless fundoplication using esophyX: 12-month results of a prospective multicenter study. World J Surg 32(8):1676–1688PubMedCentralPubMedCrossRef Cadière G, Buset M, Muls V, Rajan A, Rösch T, Eckardt A et al (2008) Antireflux transoral incisionless fundoplication using esophyX: 12-month results of a prospective multicenter study. World J Surg 32(8):1676–1688PubMedCentralPubMedCrossRef
11.
go back to reference Ross S, Roddenbery A, Luberice K, Paul H, Farrior T, Vice M et al (2013) Laparoendoscopic single site (LESS) vs. conventional laparoscopic fundoplication for GERD: is there a difference. Surg Endosc 27(2):538–547PubMedCrossRef Ross S, Roddenbery A, Luberice K, Paul H, Farrior T, Vice M et al (2013) Laparoendoscopic single site (LESS) vs. conventional laparoscopic fundoplication for GERD: is there a difference. Surg Endosc 27(2):538–547PubMedCrossRef
12.
go back to reference Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862–3868PubMed Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH (2001) Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 7:3862–3868PubMed
13.
go back to reference Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med 369:1691–1703CrossRef Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med 369:1691–1703CrossRef
14.
go back to reference Cowgill SM, Villadolid D, Al-Saadi S, Rosemurgy AS (2007) Difficult myotomy is not determined by preoperative therapy and does not impact outcome. JSLS 11(3):336–343PubMedCentralPubMed Cowgill SM, Villadolid D, Al-Saadi S, Rosemurgy AS (2007) Difficult myotomy is not determined by preoperative therapy and does not impact outcome. JSLS 11(3):336–343PubMedCentralPubMed
15.
go back to reference Desai N, Trieu V, Damascelli B, Soon-Shiong P (2009) SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2(2):59–64PubMedCentralPubMedCrossRef Desai N, Trieu V, Damascelli B, Soon-Shiong P (2009) SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2(2):59–64PubMedCentralPubMedCrossRef
16.
go back to reference Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gabele E, Hinke A, Hollerbach C, Endlicher E (2009) Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicenter phase II study. Br J Cancer 100:1032–1036PubMedCentralPubMedCrossRef Kullmann F, Hollerbach S, Dollinger MM, Harder J, Fuchs M, Messmann H, Trojan J, Gabele E, Hinke A, Hollerbach C, Endlicher E (2009) Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicenter phase II study. Br J Cancer 100:1032–1036PubMedCentralPubMedCrossRef
17.
go back to reference Merchan JR, Ferrell A, Macintyre J et al (2000) Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Cancer Chemother Pharmacol 67:891–897 Merchan JR, Ferrell A, Macintyre J et al (2000) Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer. Cancer Chemother Pharmacol 67:891–897
18.
go back to reference Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin LX, D’Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, O’Reilly EM, Allen PJ (2012) A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 7(7):e40157PubMedCentralPubMedCrossRef Winter JM, Tang LH, Klimstra DS, Brennan MF, Brody JR, Rocha FG, Jia X, Qin LX, D’Angelica MI, DeMatteo RP, Fong Y, Jarnagin WR, O’Reilly EM, Allen PJ (2012) A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. PLoS One 7(7):e40157PubMedCentralPubMedCrossRef
19.
go back to reference Chen SH, Hung W-C, Wang P, Paul C, Konstantopoulos K (2013) Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 3:1870PubMedCentralPubMed Chen SH, Hung W-C, Wang P, Paul C, Konstantopoulos K (2013) Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation. Sci Rep 3:1870PubMedCentralPubMed
20.
go back to reference Hernandez JRS, Morton C, McFarlin K, Dahal S, Golkar F, Albrink M, Rosemurgy A (2010) The learning curve of laparoendoscopic single-site (LESS) cholecystectomy: definable, short, and safe. J Am Coll Surg 211(5):652–657PubMedCrossRef Hernandez JRS, Morton C, McFarlin K, Dahal S, Golkar F, Albrink M, Rosemurgy A (2010) The learning curve of laparoendoscopic single-site (LESS) cholecystectomy: definable, short, and safe. J Am Coll Surg 211(5):652–657PubMedCrossRef
21.
go back to reference Hernandez JM, Morton C, Ross S, Albrink M, Rosemurgy AS (2009) Laparoendoscopic single site cholecystectomy: the first 100 patients. Am Surg 75(8):681–685PubMed Hernandez JM, Morton C, Ross S, Albrink M, Rosemurgy AS (2009) Laparoendoscopic single site cholecystectomy: the first 100 patients. Am Surg 75(8):681–685PubMed
22.
go back to reference Ross SB, Hernandez J, Sperry S, Morton CA, Vice M, Luberice K, Rosemurgy AS (2012) Public perception of LESS surgery and NOTES. J Gastrointest Surg 16(2):344–355PubMedCrossRef Ross SB, Hernandez J, Sperry S, Morton CA, Vice M, Luberice K, Rosemurgy AS (2012) Public perception of LESS surgery and NOTES. J Gastrointest Surg 16(2):344–355PubMedCrossRef
23.
go back to reference Golkar FC, Ross SB, Sperry S, Vice M, Luberice K, Donn N, Morton C, Hernandez JM, Rosemurgy AS (2012) Patients’ perceptions of laparoendoscopic single-site surgery: the cosmetic effect. Am J Surg 204(5):751–761PubMedCrossRef Golkar FC, Ross SB, Sperry S, Vice M, Luberice K, Donn N, Morton C, Hernandez JM, Rosemurgy AS (2012) Patients’ perceptions of laparoendoscopic single-site surgery: the cosmetic effect. Am J Surg 204(5):751–761PubMedCrossRef
24.
go back to reference Ross SB, Luberice K, Kurian TJ, Paul H, Rosemurgy AS (2013) Defining the learning curve of laparoendoscopic single-site Heller myotomy. Am Surg 79(8):837–844PubMed Ross SB, Luberice K, Kurian TJ, Paul H, Rosemurgy AS (2013) Defining the learning curve of laparoendoscopic single-site Heller myotomy. Am Surg 79(8):837–844PubMed
Metadata
Title
Does the cost of robotic cholecystectomy translate to a financial burden?
Authors
Alexander Rosemurgy
Carrie Ryan
Richard Klein
Prashant Sukharamwala
Thomas Wood
Sharona Ross
Publication date
01-08-2015
Publisher
Springer US
Published in
Surgical Endoscopy / Issue 8/2015
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-014-3933-8

Other articles of this Issue 8/2015

Surgical Endoscopy 8/2015 Go to the issue